Pharma Focus Asia

Genenta Science Announces Extension of Licence Agreement with Ospedale San Raffaele

Tuesday, April 04, 2023

Genenta announced that the licence agreement with Ospedale San Raffaele (OSR) has been amended and restated to provide access to all solid tumour indications, subject to governmental consent as described below.

This agreement will strengthen the breadth of IP position and confirm options for combination treatments and other potential payloads. Promising preliminary clinical data generated in the ongoing study of the first solid tumour indication in glioblastoma supports decision to expand the licence to cover all solid tumours and primes ability to impact other hard-to-treat cancer types.

The amended and restated licence agreement reinforces Genenta's long-term strategic relationship with OSR, contributing to the unique and valuable expertise for the development of cell-based therapies.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024